Eli Lilly (NYSE:LLY) is scheduled to announce Q4 earnings results on Thursday, February 6th, before market open. The ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...

The upcoming report from Eli Lilly (LLY) is expected to reveal quarterly earnings of $5.15 per share, indicating an increase of 106.8% compared to the year-ago period. Analysts forecast revenues of ...

Earnings Report 5.125 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 5.041 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.723 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

I think Eli Lilly and Company's stock correction may be ... remarks regarding the near-term sales dynamics, now expecting Q4 revenue of ~$13.5 billion (Fy2024 revenue of ~$45 billion), a bit ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.